MedTech logo
 
 
 
 
 
 
temp_image_2

t: 0161 820 8440

e:  

News

Zilico gets a step nearer to the market

Zilico Ltd has received EC certification from its Notified Body for ZedScan I, a cervical cancer diagnostics device.

 

The UK company’s ground-breaking system offers quicker and more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management. The ZedScan I system is used alongside colposcopy on women identified with an abnormal smear result. ZedScan offers clinical benefits by identifying the optimum biopsy site and so reducing the number of cervical biopsies required whilst also facilitating a wider use of 'select & treat'.

As well as its clinical benefits, a recent independent health economics report demonstrated that ZedScan delivers cost-effective benefits to healthcare systems.

Zilico’s patented Electrical Impedance Spectroscopy (EIS) technology exploits the different electrical resistivity of normal, pre-cancerous and cancerous tissue.

The system, which is both safe and painless, consists of a portable hand-held device and docking station, software application and a single-use EIS sensor. Five clinical trials in the UK and EU have supported the clinical efficacy of ZedScan, including a pivotal European trial of 429 women in 2011 across three hospitals in the UK and Ireland.

The company has been presenting these results at key scientific meetings and high-profile healthcare conferences across the world, including ASCCP 2012 at which it received the ‘Best Scientific Presentation’ award.

Following EC certification, ZedScan is being introduced into a number of clinics in the UK and healthcare systems across the globe.

Sameer Kothari, Chief Executive of Zilico Ltd, said: “ZedScan has the potential to make a significant impact on how women are managed within the cervical cancer pathway by providing better information to the clinician in real-time and its European approval is an important advancement for clinicians, healthcare systems and patients.

ZedScan has generated substantial interest from clinicians across the globe through various presentations, conferences and clinical meetings and we now look forward to being able to satisfy the growing demand as colposcopy clinics seek to implement this breakthrough system and exploit the clinical and health economic benefits it will bring through better patient management.”

back to news listing

Supported by:


Central Manchester University Hospitals logoManchester Science Parks logoTrusTECH logo